The technology acquisition supports Bruker's microbiology business and its MALDI Biotyper microbial identification platform. The company did not disclose financial details.

The assets include laboratory infrastructure and IP in the Nucleic Acid Testing (NAT) assay field including real time Polymerase chain reaction (PCR) assays for microbiology.

Also, Bruker appointed an R&D, operations and commercial team in Glasgow to develop the PCR-based syndromic panel development for its MALDI Biotyper platform.

MALDI Biotyper is claimed to be a fast, accurate and cost efficient microbial identification with broad species coverage based on proteomic fingerprinting. Molecular multiplex and syndromic panel testing is also a developing field in clinical microbiology.

Multiple PCR assays can be used for identifying selected bacterial, fungal and viral species and in quickly detecting resistance genes, when rapid and targeted answer is required without prior microbial cultivation. These proteomic assays and NAT assays can both be done on the same MALDI Biotyper platform.

Bruker Daltonics Clinical MALDI Solutions executive vice president Wolfgang Pusch said:  "In addition to conventional, targeted real-time PCR assays, Bruker sees further advantages in combining multiplexed syndromic PCR assays with a read-out on the MALDI Biotyper platform.  

“Bruker intends to validate and launch the real-time PCR assays which have been acquired, and develop new multiplex PCR panels on the MALDI Biotyper platform in order to expand its assay menu to rapid targeted bacterial, fungal and viral identification, to fast antibiotic resistance testing, as well as to syndromic panels. 

"With over 2,000 MALDI Biotypers already installed worldwide for fast, highly accurate and untargeted microbial identification, we are excited to bring new NAT multiplex assay and syndromic panel capabilities to our customers over time."